RESEARCH ARTICLE

Acceleration of the DNA methylation clock among Lynch syndrome-associated mutation carriers

Marta Cuadros1,8,9*, Carlos Cano2*, Sonia García-Rodríguez2,8*, José Luis Martín3, Antonio Poyatos-Andujar3, Francisco Ruiz-Cabello4, Susana Pedrinaci4, Gema Durán5, Manuel Benavides5, María Dolores Bautista-Ojeda6, Teresa Pereda6, María Soledad Benitez-Cantos1,8, Pedro Medina8,9,10, Armando Blanco2, Antonio González7 and Paul Lizardi8

Abstract

Background: DNA methylation (DNAm) age metrics have been widely accepted as an epigenetic biomarker for biological aging and disease. The purpose of this study is to assess whether or not individuals carrying Lynch Syndrome-associated mutations are affected in their rate of biological aging, as measured by the epigenetic clock.

Methods: Genome-wide bisulfite DNA sequencing data were generated using DNA from CD4+ T-cells obtained from peripheral blood using 27 patient samples from Lynch syndrome families. Horvath's DNAm age model based on penalized linear regression was applied to estimate DNAm age from patient samples with distinct clinical and genetic characteristics to investigate cancer mutation-related aging effects.

Results: Both Lynch mutation carriers and controls exhibited high variability in their estimated DNAm age, but regression analysis showed steeper slope for the Lynch mutation carriers. Remarkably, six Lynch Syndrome-associated mutation carriers showed a strong correlation to the control group, and two sisters carrying Lynch Syndrome-associated mutations, with no significant difference in lifestyle and similar chronological age, were assigned very different DNAm age.

Conclusions: Future studies will be required to explore, in larger patient populations, whether specific epigenetic age acceleration is predictive of time-to-cancer development, treatment response, and survival. Epigenetic clock DNAm metrics may be affected by the presence of cancer mutations in the germline, and thus show promise of potential clinical utility for stratified surveillance strategies based on the relative risk for imminent emergence of tumor lesions in otherwise healthy Lynch Syndrome-associated mutation carriers.

Keywords: DNA methylation, Lynch syndrome, Epigenetic clock

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
whose methylation status is used with a regression algorithm to estimate the biological age of a DNA sample obtained from an individual [4]. Current views regarding the significance of epigenetic clock metrics suggest that DNAm clocks capture aging-related epigenetic modifications that are widespread and indicative of genomic, cell biology, and tissue changes that occur throughout life. These molecular changes could lead to a more precise and high-resolution knowledge of age-related disease and physiology, according to a recent review by Bell et al., 2019 [5]. Patients with HIV infection and Down syndrome have been found to have accelerated DNAm aging [3]. In addition, a large body of literature has identified DNAm as one of the key mechanisms underlying the association between aging and cancer [6, 7], showing epigenetic age acceleration might represent an early event in the development of cancerous cells and could be utilized to predict cancer risk and cancer incidence [8].

Several DNAm clocks have been proposed in the literature [4, 5]. These predictors are trained on data from different platforms and tissues, hence some variability between their predictions has been reported [5]. The clock reported by Hannum et al. [9] relied on 71 CpGs from the Illumina 450 K array, using DNA obtained from human peripheral blood samples. Horvath et al. proposed a “pan-tissue” DNAm clock [10] comprised of a subset of 353 CpGs present in the Illumina 27 k array. Recently, DNAm clocks have been proposed that are trained on age-related and disease phenotypes, such as the “PhenoAge” DNA methylation clock [4] or the “Grim Age” clock [11]. While these clocks lead to a stronger prediction on lifespan and healthspan, they are not solely based on methylation signals but require more information such as age-related biochemical measures or smoking related habits [11].

Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, represents around 5% of colorectal cancers (CRC) and, it is transmitted in an autosomal dominant manner. Carriers of the different Lynch Syndrome-associated mutations in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2 [12]) have a significantly higher risk of developing colorectal cancer in first-degree. Moreover, these patients also have a higher risk of developing other tumor types, as endometrial adenocarcinoma, affecting at least to one female relative in 50% of Lynch syndrome pedigrees, stomach, small intestine, liver, biliary tract, brain, and ovary cancers, as well as transition cell carcinoma in ureters and renal pelvis. The average age of CRC detection in carriers of any of these mutations is in the mid 40 s to early 50 s, in contrast to the 60 years average age of onset for other sporadic CRC patients [13].

Colonoscopic and gynecological monitoring is recommended for patients with a germline mutation in MMR genes [14, 15]. Healthy carriers of Lynch Syndrome-associated mutations are subject to a psychological burden by the knowledge that a cancer lesion is likely to emerge at any time. Physicians monitoring the health of these individuals need reliable metrics of imminent cancer risk to be able to prioritize care for the most severely affected individuals. Here we show data suggesting that DNA methylation metrics in general, and the epigenetic clock in particular, may be of utility in monitoring imminent cancer risk in healthy carriers of Lynch Syndrome-associated mutations.

**Methods**

**Patients**

18 Lynch syndrome patients without tumor and nine healthy relatives from 13 different families (shown in

| Sample | Sex | Mutation | Age at diagnosis | Family |
|--------|-----|----------|------------------|--------|
| HC1    | Female | Negative | 24 | Fam1 (MSH6) |
| HC2    | Male | MSH6 | 21 | |
| HC3    | Female | MSH6 | 51 | Fam2 (MSH6) |
| HC4    | Female | MSH6 | 52 | |
| HC5    | Female | Negative | 57 | |
| HC7    | Female | Negative | 50 | |
| HC8    | Male | MSH6 | 40 | Fam3 (MSH6) |
| HC9    | Female | MSH6 | 38 | |
| HC11   | Male | MLH1 | 43 | Fam4 (MLH1) |
| VN1    | Female | MSH6 | 36 | Fam5 (MSH6) |
| VN2    | Male | MSH6 | 40 | |
| VN3    | Female | Negative | 30 | |
| VN4    | Male | Negative | 39 | |
| VN10   | Female | MSH6 | 41 | |
| VN6    | Female | MLH1 | 34 | Fam6 (MLH1) |
| VN8    | Female | Negative | 33 | |
| VN9    | Female | Negative | 28 | |
| VN7    | Male | PMS2 | 29 | Fam7 (PMS2) |
| M2     | Female | Negative | 64 | Fam8 |
| M3     | Male | MSH2 | 55 | Fam9 (MSH2) |
| M6     | Female | Negative | 34 | Fam10 (MCH1) |
| M7     | Male | MCH1 | 30 | |
| M8     | Male | MLH1 | 42 | Fam11 (MLH1) |
| M9     | Female | MLH1 | 44 | |
| M10    | Male | MLH1 | 37 | Fam12 (MLH1) |
| M11    | Female | MLH1 | 32 | |
| M12    | Female | MSH2 | 44 | Fam13 (MSH2) |
Table 1) provide peripheral blood samples for isolation of CD4+ cells. All patients with documented mutations in our study are members of large “Lynch family” cohorts. In each of these Lynch families known relatives have died from CRC caused by Lynch syndrome-associated mutations. The CRC tumors in affected family members contained germline mutations and displayed microsatellite instability, indicating that the Lynch syndrome-associated mutations are pathogenic. Samples were obtained from the Hospital Universitario San Cecilio (Granada, Spain), Hospital Virgen de las Nieves (Granada, Spain) and Hospital Regional Universitario Carlos Haya (Málaga, Spain). Participants provided written consent in accordance with the procedures of the Declaration of Helsinki and the institutional and national guidelines.

Library synthesis
Peripheral blood mononuclear cells were obtained from patient blood samples by ficoll-hypaque (GE Healthcare) gradient. Dynabeads® CD4 Positive Isolation Kit (Thermo Fisher Scientific, MA, USA) was used to separate CD4+ cells. Genomic DNA was isolated from CD4+ cells using DNeasy Mini Kit (Qiagen, Carlsbad, CA). All protocols were made according to manufacturer’s procedures. Libraries were generated using the SureSelectXT Human Methyl-Seq (Agilent) Targeted Enrichment Kit (Agilent Technologies, Santa Clara, CA). Combining the SureSelectXT system and bisulfite conversion, studying 80 Mb and covering over 3.7 million CpGs. Samples were processed following the recommended Methyl-Seq protocol Version B, January 2013. The samples target sequences were bisulfite converted using the EZ DNA Methylation-Gold kit (Zymo Research) as described in the Methyl-Seq protocol.

DNA methylome sequencing
Indexed and pooled libraries were sent to the CNAG-CRG Sequencing Unit in Barcelona, Spain for DNA sequencing. Sequencing was performed on the Illumina HiSeq2000 instrument (100 bp paired-end reads, 40 million reads per sample, representing 50X to 80X coverage). The sequencing reads were processed at CNAG-CGR in Barcelona and provided to us as fastq files.

Computational analysis of methylation data
The computational analysis of the data is depicted in Fig. 1. First, the raw reads underwent a quality control analysis with FastQC (https://github.com/s-andrews/).
FastQC). Second, we used Bismark [16] for BS-Seq alignment and computing the methylation ratios for all the CpG sites in the Agilent SureSelectMethylKit. Results of the alignment showed an average coverage of 61X (std ± 25) for the different samples. Horvath’s methylation age computation is based on the methylation beta values of 353 CpGs included in the Illumina450K arrays [4]. This estimation is computed as a linear combination of the beta values of these 353 CpGs using the coefficients for each CpG provided by the authors. After mapping these coordinates from Genome build 36 to Genome build 37 and using samtools to intersect Agilent SureSelectMethylKit target CpG sites with Horvath’s methylation age signature, we got a total of 317 CpG coordinates. Therefore, 36 CpGs from Horvath’s methylation age signature could not be considered. With the remaining 317 CpG methylation values, we computed Horvath’s methylation age using the R code distributed by the authors [4].

A linear regression was carried out separately for Lynch and Control samples using the values of age and estimated methylation with function lm in R [17].

**Results**

In the present study, we compiled peripheral blood DNA methylation data, generated using target enrichment and bisulfite DNA sequencing. Target enrichment was performed using the Methyl-Seq Analysis Platform (Agilent kit, see Methods). The study cohort consisted of 18 subjects who had previously confirmed clinical and molecular diagnoses of Lynch syndrome (caused by germline mutation in one of the MMR genes, MLH1, MSH2, MSH6, or PMS2), and 9 family relatives without the mutation. All patients were healthy and had no clinical evidence of Lynch syndrome associated tumors at the date of peripheral blood extraction (Table 1).

For the 27 samples, we computed the DNAm clock by Horvath et al. [4] and compared the obtained methylation age (mAge) to the chronological age. The correlation between mAge and Age (Fig. 2) was higher for the Lynch Syndrome-associated mutation carriers group (Multiple $R^2 = 0.27$, $p$ value = 0.026) than for the control group (Multiple $R^2 = 0.23$, $p$ value = 0.182). Both groups exhibited high variability in their estimated mAge. $R^2$ values are below 30%, indicating that more variables are needed (apart from chronological age) to explain the variance of mAge. However, there are some striking cases which draw our attention in these preliminary results. One of these examples is samples HC3 and HC4, members of the same family (sisters). HC3, a carrier of a Lynch Syndrome-associated mutation does not correlate with the regression line for Lynch syndrome-associated mutation carriers, but with the regression line for control cases. The computed DNAm age for HC3 was 33% lower than the corresponding chronological age (DNAm age of 33.75 and chronological age of 51). This result is surprising, since HC4 is only 1 year older than HC3 (52 years old, at the date of the study). It is unfortunate that we do not have potentially relevant clinical data for each patient regarding differences in lifestyle (cigarette smoking, oral contraceptives, etc.). Regarding relevant clinical variables affecting the two sisters we do know the time of the endocrine disruption produced by hysterectomy. While HC3 was hysterectomized 5 years before the date of the study, HC4 was hysterectomized 20 years earlier, with a potential influence of time of surgery on epigenetic age. It is also striking that six cases which are carriers of Lynch syndrome-associated mutations (M10, HC8, VN2, VN10, M9, and HC3) have DNAm metrics that fall within the 95% confidence interval for the regression line of the nine “normal” cases that are not mutation carriers. One possible interpretation that could explain the “normal” DNAm metrics of these six cases is that in these individuals the loss of the remaining functional allele in somatic cells of the colon epithelium has not yet occurred, and microsatellite instability is not yet prevalent in epithelial cells. To further evaluate this possible interpretation, we note that among these six individuals, four are carriers of the MSH6 mutation, for which the time of onset of CRC is known to be delayed by approximately nine years, compared to MLH1 and MSH2 mutation carriers [18]. The other two cases are carriers of the MLH1 mutation, and are 37 and 44 years old, respectively. The data in the Ryan et al. study [18] showed that approximately 50% of MLH1 mutation carriers develop CRC tumors after the age of 46, therefore it is possible that DNAm metrics for these two individuals reflect their excellent health status, mediated by a delay in the onset of mismatch repair defects and microsatellite instability. In Fig. 3 we show a modified DNAm scatter plot of all 27 cases, in which we have excluded the six mutation-carrying outliers (highlighted in green) from the linear regression analysis of the Lynch mutation carriers. The slope of the regression line for the 12 remaining mutation carriers (highlighted in red) is now steeper, possibly reflecting the deteriorating health status and acceleration of the epigenetic clock in the subset of mutation carriers for whom microsatellite instability and a high mutational burden are already prevalent in colonic tissues.

**Discussion**

The data obtained in this study shows that the majority of individuals carrying Lynch syndrome-associated mutations display an acceleration of the epigenetic clock, as defined by the Horvath CpG methylation metrics. However, six out of 18 individuals with genetically documented mutations did not show acceleration of the
Physicians monitoring the health of individuals known to be carriers of Lynch mutations need reliable metrics of relative cancer risk to be able to assess and prioritize care according to the likelihood of the imminent appearance of a cancer lesion. Here we show data indicating that DNA methylation metrics may be able to stratify carriers and non-carriers on the basis of the rate of biological aging as defined by the epigenetic clock. With follow-up studies involving a larger number of subjects, it may be possible to refine these biomarkers of the biological aging process, so they can be of utility in monitoring imminent cancer risk in healthy carriers of Lynch Syndrome-associated mutations. When fully developed, these DNAm biomarkers could be of potential clinical utility for stratified surveillance strategies that will facilitate cancer prevention in Lynch syndrome patients. Prospective studies, where the biological age based on the epigenetic clock is
measured every year until cancers actually appear in certain individuals have potential to reveal additional correlations or insights, such as the possibility of accelerated biological aging just before the time of tumor emergence.

We note that our study has certain limitations relating to statistical significance, due to the small sample size of the patient population. In addition, the clinical annotation of the subjects who participated in the study suffers from lack of data relating to nutrition habits and lifestyle choices, such as contraceptives, alcohol consumption, smoking, etc. These limitations could be addressed by performing studies with larger numbers of Lynch syndrome patients, and also by collecting samples from the same individuals every year in order to generate longitudinal data sets.
Conclusions

Epigenetic clock DNAm metrics may be affected by the presence of cancer mutations in the germline, and thus show promise of potential clinical utility for assessment of relative risk related to imminent emergence of tumor lesions in otherwise healthy Lynch Syndrome-associated mutation carriers.

Abbreviations

DNAm: DNA methylation; DNAm clock: DNA methylation clock; HNPCC: Hereditary nonpolyposis colorectal cancer; CCR: Colorectal cancer; MMR: Mismatch repair.

Acknowledgements

This work has been carried out as part of Projects CAIXA2017/1 of “la Caixa” Foundation, and DPI2017-84439-R of MINECO, Madrid and FEDER and A-BIO-470-UGR20 from University of Granada and FEDER.

Authors’ contributions

MC, CC, AB, AG and PL, Conceptualization; CC, Data curation; CC and PL, Formal analysis; MC, CC, AB, AG and PL, Funding acquisition; MC, JLM, APA, FRC, SP, GD, MB, MD80, PM and TP, Investigation; MC, CC, AB, PL, PM and AG, Methodology; AB and PL, Project administration; MC, CC, AB and PL, Resources; CC and MSB, Software; MC, CC, AB and PL, Supervision; CC, Validation; CC, MSB, AB and PL, Visualization; MC, CC, AB and PL, Writing—original draft; CC, PL, AB, MSB and SGR, Writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

The research leading to these results has received funding from “la Caixa” Foundation (Reg: CAIXA2017/1) for library preparation, sequencing, and employment of research personnel, from the Fundación Progreso y Salud, Junta de Andalucía, Spain and from DPI2017-84439-R of MINECO, Madrid and FEDER for sequencing and employment of research personnel. Finally, grant ref. A-BIO-470-UGR20 from University of Granada and FEDER has funded article processing charges (APC) and sample processing expenses.

Availability of data and materials

Bisulfite-Seq data are available at NCBI BioProject and Sequence Read Archive with Accession Number: PRJNA804259. http://www.ncbi.nlm.nih.gov/bioproject/804259, https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA804259.

Declarations

Ethics approval and consent to participate

The research protocol referenced in this manuscript abided by Declaration of Helsinki and the institutional and national guidelines and has been approved by the Ethics Committee “Comité Ético de Investigación” (CEI/CEIm) of Granada, member of the Ethics Committee of the Andalusian Public Health Service (“Servicio Sanitario Público de Andalucía”). This authorization, together with the written informed consent obtained from all subjects involved in the study, allowed our team to access the clinical/personal patient data used in this research.

Consent for publication

Written informed consent was obtained from the patients for publication of this paper.

Competing interests

The authors declare no conflict of interest.

Author details

1Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada. 2Department of Computer Science and Artificial Intelligence, University of Granada. 3Hospital Universitario San Cecilio, Granada, Spain. 4Hospital Virgen de Las Nieves, Granada, Spain. 5Hospital Regional Universitario Carlos Haya, Málaga, Spain. 6Hospital Costa del Sol, Marbella, Spain. 7Instituto de Parasitología y Biomedicina López-Neyra – CSIC, Granada, Spain. 8GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Av. de la Ilustración 114, 18007 Granada, Spain. 9Health Research Institute of Granada (IbsiGranada), Av. Fuerzas Armadas 2, 18014 Granada, Spain. 10Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Av. de Fuente Nueva S/N, 18071 Granada, Spain.

Received: 18 June 2021 Accepted: 15 February 2022 Published online: 04 March 2022

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca Cancer J Clin. 2018;68(1):7–30.
2. Risques RA, Kennedy S. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14(1):e1007108.
3. Perkovich DA, Podolsky D, Lobanov AV, Lee S-G, Miller RA, Gladyshev VN. Using DNA methylation profiling to evaluate biological age and longevity interventions. Cell Metab. 2017;25(4):954–960.eb.
4. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371–84.
5. Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019;20:249.
6. López-Otín C, Basco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.
7. Aunan JR, Cho WC, Soreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular Hallmarks. Aging Dis. 2017;8(5):628–42.
8. Perna L, Zhang Y, Mons U, Holleczek B, Saum KU, Brenner H. Epigenetic age acceleration predict cancer, cardiovascular, and all-cause mortality in a German case cohort. Clin Epigenet. 2016;8:64.
9. Hanumm M, Guiney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359–67.
10. Horvath S. DNA methylation age of human tissues and cells types. Genome Biol. 2013;14(10):R115.
11. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(12):303–27.
12. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins M. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 2015;15(3):181–94.
13. Jaspersen KW, Vu TM, Schwab AL, Nelkonson DW, Rodriguez-Bigas MA, Burt R, et al. Evaluating Lynch syndrome in very early onset colorectal cancer patients without apparent polyposis. Fam Cancer. 2010;9(2):99–107.
14. Syngal S, Brand RE, Chuhrm JM, Giardello FM, Hampel HL, Burt JM. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–63.
15. Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, et al. The Manchester International Consensus Group recommendations for the management of gynaecological cancers in Lynch syndrome. Genet Med. 2019;21(10):2390–2340.
16. Krueger F, Andrews SR. Bismark: A flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 2011;27(10):1571–2.
17. Chambers JM. Linear models. In: Chambers JM, Hastie TJ (eds) Chapter 4 of statistical models in S. Wadsworth & Brooks/Cole, Pacific Grove, 1992;pp 95–146.
18. Ryan NAJ, Morris J, Green K, Laloff F, Woodward EA, Hill J, Crosbie EJ, Evans G. Association of mismatch repair mutation with age at Cancer onset in Lynch syndrome; Implications for stratified surveillance strategies. JAMA Oncol. 2017;3(12):1702–6.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.